BNP Paribas Arbitrage SA increased its position in shares of Insulet Corporation (NASDAQ:PODD) by 407.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,797 shares of the medical instruments supplier’s stock after acquiring an additional 6,260 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Insulet Corporation were worth $400,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. FMR LLC boosted its position in Insulet Corporation by 0.4% during the first quarter. FMR LLC now owns 8,647,651 shares of the medical instruments supplier’s stock worth $372,628,000 after acquiring an additional 33,745 shares during the last quarter. Vanguard Group Inc. boosted its position in Insulet Corporation by 4.2% during the first quarter. Vanguard Group Inc. now owns 4,556,847 shares of the medical instruments supplier’s stock worth $196,355,000 after acquiring an additional 184,465 shares during the last quarter. BlackRock Inc. boosted its position in Insulet Corporation by 7,285.2% during the first quarter. BlackRock Inc. now owns 4,194,117 shares of the medical instruments supplier’s stock worth $180,724,000 after acquiring an additional 4,137,326 shares during the last quarter. Clearbridge Investments LLC boosted its position in Insulet Corporation by 64.2% during the first quarter. Clearbridge Investments LLC now owns 2,379,224 shares of the medical instruments supplier’s stock worth $102,521,000 after acquiring an additional 930,062 shares during the last quarter. Finally, Frontier Capital Management Co. LLC boosted its position in Insulet Corporation by 11.9% during the first quarter. Frontier Capital Management Co. LLC now owns 1,759,454 shares of the medical instruments supplier’s stock worth $75,815,000 after acquiring an additional 187,577 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: “BNP Paribas Arbitrage SA Has $400,000 Position in Insulet Corporation (PODD)” was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/09/17/bnp-paribas-arbitrage-sa-has-400000-position-in-insulet-corporation-podd.html.

In related news, EVP Charles Alpuche acquired 2,500 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were purchased at an average price of $58.08 per share, for a total transaction of $145,200.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.90% of the stock is currently owned by corporate insiders.

Insulet Corporation (PODD) opened at 59.46 on Friday. The firm’s market cap is $3.45 billion. The firm has a 50 day moving average of $55.64 and a 200-day moving average of $47.58. Insulet Corporation has a one year low of $30.69 and a one year high of $59.97.

Insulet Corporation (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $110.00 million for the quarter, compared to analyst estimates of $106.23 million. Insulet Corporation had a negative net margin of 7.30% and a negative return on equity of 46.74%. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.08) EPS. Equities research analysts forecast that Insulet Corporation will post ($0.50) EPS for the current fiscal year.

PODD has been the topic of a number of analyst reports. Piper Jaffray Companies restated an “overweight” rating and set a $47.00 target price on shares of Insulet Corporation in a research report on Monday, May 22nd. William Blair restated an “outperform” rating on shares of Insulet Corporation in a research report on Thursday, May 25th. Canaccord Genuity restated a “hold” rating and set a $42.00 target price on shares of Insulet Corporation in a research report on Friday, May 26th. ValuEngine upgraded shares of Insulet Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Jefferies Group LLC restated a “buy” rating on shares of Insulet Corporation in a research report on Friday, June 16th. Eight analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $51.50.

Insulet Corporation Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD).

Institutional Ownership by Quarter for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.